Recent advance in carbohydrate-based cancer vaccines / 药学学报
Acta Pharmaceutica Sinica
; (12): 261-270, 2012.
Article
in Zh
| WPRIM
| ID: wpr-323047
Responsible library:
WPRO
ABSTRACT
The abnormal glycans expressing on the surface of tumor cells are good targets to develop carbohydrate-based anti-cancer vaccines. However, one of the major problems is that carbohydrate antigens possess weak immunogenicity. This review summarizes the recent efforts to overcome this problem: glycoconjugates produced by coupling the carbohydrate antigens and proper carrier proteins improve their immunogenicity, many glycoconjugates have entered clinical trials; the vaccines become chemically well-defined when coupling the carbohydrate antigens with a T-cell peptide epitope and an immunostimulant to form fully synthetic multi-component glycoconjugate vaccines; the modification of carbohydrate antigens in combination with the technology of metabolic oligosaccharide engineering of tumor cells induces a strong immune response; and the fact that the antibodies elicited against the unnatural carbohydrate antigens can recognize the native carbohydrate antigens on tumor cells provides a new promising strategy for the development of anti-cancer vaccines.
Full text:
1
Index:
WPRIM
Main subject:
Oligosaccharides
/
Therapeutics
/
Carbohydrates
/
Glycoconjugates
/
Antigens, Tumor-Associated, Carbohydrate
/
Chemistry
/
Epitopes, T-Lymphocyte
/
Cancer Vaccines
/
Therapeutic Uses
/
Allergy and Immunology
Limits:
Animals
/
Humans
Language:
Zh
Journal:
Acta Pharmaceutica Sinica
Year:
2012
Type:
Article